A proposal by the Biden Administration to change how prescription drug rebates are calculated in the Medicaid program could have ripple effects that could affect drug pricing and accessibility throughout multiple markets, according to this analysis prepared by the Avalere healthcare consulting and advisory firm and released by HLC.
Proposed Changes to Best Price Could Shift Market Dynamics for Stakeholders
- Topics: Access, Competition, Innovation, Medicaid, Medicare
Related Reports
Setting the Record Straight: The Facts Behind MedPAC’s Misleading Cost Analysis of Medicare Advantage
Our latest report challenges the accuracy of recent MA spending estimates by MedPAC, exposing critical flaws in the Commission’s revised methodology underpinning its skewed estimates, and calls for greater transparency in evaluating the MA program.
Cybersecurity in Healthcare: Defining Private and Public Sector Responsibility
As life-threatening and financially crippling cyberattacks increase, a new report from HLC and HLC’s Confidentiality Coalition, proposes a collaborative public-private framework to safeguard the healthcare system. Co-authored by Manatt, Phelps & Phi…
Analysis of CMMI Model Costs, Quality Performance, and Transparency
A new Avalere Health analysis commissioned by HLC evaluates the performance of 18 Center for Medicare and Medicaid Innovation (CMMI/Center) payment models revealing opportunities to further improve patient outcomes and deliver savings.
